Terns Pharmaceuticals (TERN) Sees Price Target Raised by 75.91% to 54.63
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 21 2025
0mins
Source: NASDAQ.COM
Price Target Update: The average one-year price target for Terns Pharmaceuticals has been revised to $54.63 per share, reflecting a 75.91% increase from the previous estimate of $31.05. The new target range from analysts is between $17.17 and $73.50 per share.
Fund Sentiment: There are currently 271 funds reporting positions in Terns Pharmaceuticals, a decrease of 4.24% from the last quarter. The average portfolio weight for these funds has increased by 47.86%, with total shares owned by institutions rising by 6.16% to 94,932K shares.
Shareholder Activity: Soleus Capital Management has slightly reduced its holdings in Terns Pharmaceuticals, while other major shareholders like Orbimed Advisors and Deep Track Capital have maintained their positions. Commodore Capital has significantly increased its stake by 100%.
Research Platform: Fintel provides comprehensive investing research tools, including fundamentals, analyst reports, ownership data, and options sentiment, aimed at individual investors and small hedge funds for improved investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TERN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TERN
Wall Street analysts forecast TERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 53.75 USD with a low forecast of 35.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.200
Low
35.00
Averages
53.75
High
60.00
Current: 34.200
Low
35.00
Averages
53.75
High
60.00
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics CEO Highlights Broad Strategic Interest in Weight-Loss Drug Deals, Shares Surge 17%
- Stock Surge: Shares of Viking Therapeutics (VKTX) surged 17% on Wednesday, reflecting strong market interest in its weight-loss drug development, particularly as Novo Nordisk (NVO) seeks acquisitions to enhance its drug portfolio.
- M&A Activity: Novo Nordisk halted its $10 billion bid for the smaller obesity drugmaker Metsera, but successfully acquired Akero Therapeutics for up to $5.2 billion in December, indicating its aggressive strategy in the obesity drug market.
- Clinical Trial Progress: Viking's lead candidate VK2735 demonstrated a significant average weight loss of 14.7% over 13 weeks in mid-stage trials, showcasing its potential in obesity treatment, with ongoing studies for an oral formulation of the drug.
- Market Sentiment: On Stocktwits, retail sentiment around VKTX remained in the 'extremely bullish' territory, with message volume rising from 'high' to 'extremely high', as speculation grew about Novo potentially acquiring Viking for around $10 billion, which would represent substantial upside from its current near $4 billion market cap.
Continue Reading
CleanSpark Inc. (CLSK) Jumps 14.13% Ahead of Mining Report for December 2025
- Stock Price Surge: CleanSpark's stock rose 14.13% on Friday to close at $11.55 per share, primarily driven by rising Bitcoin prices, reflecting investor optimism ahead of its upcoming December 2025 mining report.
- Bitcoin Mining Performance: In November, CleanSpark successfully mined 587 Bitcoins, bringing its total holdings to 13,054, indicating strong performance and ongoing growth potential in the Bitcoin market.
- Significant Sales Revenue: The company sold 565.41 Bitcoins at an average price of $91,979, generating total earnings of $52 million, which further solidifies its financial foundation in the Bitcoin mining sector.
- Strategic Transition: CleanSpark is gradually transitioning from Bitcoin mining to high-performance computing (HPC) services, and while the market remains optimistic about its future potential, analysts believe that other AI stocks may offer higher returns with lower risk.
Continue Reading